Characterization of Recombinant Human Coagulation Factor X_Friuli

Summary

Naturally occurring plasma factor X_Friuli (pFXFr) is marginally activated by both the extrinsic and intrinsic coagulation pathways and has impaired catalytic potential. These studies were initiated to obtain confirmation that this molecule is multi-functionally defective due to the substitution of Ser for Pro at position 343 in the catalytic domain. By the Nelson-Long site-directed mutagenesis procedure a construct of cDNA in pRc/CMV was derived for recombinant factor X_Friuli (rFXFr) produced in human embryonic (293) kidney cells. The rFXFr was purified and shown to have a molecular size identical to that of normal plasma factor X (pFX) by gel electrophoretic, and amino-terminal sequencing revealed normal processing cleavages. Using recombinant normal plasma factor X (rFXN) as a reference, the post-translational y-carboxy-glutamic acid (Gla) and (β-hydroxy aspartic acid (β-OH-Asp) content of rFXFr was over 85% and close to 100%, respectively, of expected levels. The specific activities of rFXFr in activation and catalytic assays were the same as those of pFXFr. Molecular modeling suggested the involvement of a new H-bond between the side-chains of Ser-343 and Thr-318 as they occur in anti-parallel (3-pleated sheets near the substrate-binding pocket of pFXFr. These results support the conclusion that the observed mutation in pFXFr is responsible for its dysfunctional activation and catalytic potentials, and that it accounts for the moderate bleeding tendency in the homozygous individuals who possess this variant procoagulant.

• References

• 1 Jackson CM. Factor X. In: Progress in Hemostasis and Thrombosis, Vol 7 Spaet TH. ed Grune & Stratton, Orlando, FL; 1984: 55-109
• 2 Pfeiffer RA, Ott R, Gilgenkrantz S, Alexandre P. Deficiency of coagulation factors VII and X associated with deletions of a chromosome 13(q34). Evidence from two cases with 46,XY, t(13;y)(ql l;q34). Hum Genet 1982; 62: 358-360
• 3 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-5102
• 4 Fujikawa K, Titani K, Davie EW. Activation of bovine factor X (Stuart factor): conversion of activation of factor Xaa to XaB. Proc Natl Acad Sci USA 1975; 72: 3359-3363
• 5 Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962
• 6 Girolami A, Molaro G, Lazzarin M, Scarpa R. Una nuova coagulopatia emorragica congenita dovuta alia presenza di un fattore X abnorme. Studio preliminare. Minerva med, Roma 1969; 60: 4939-4949
• 7 Girolami A, Bmnetti A, Bareggi G, Celia S. Abnormal factor X (Factor X Friuli) coagulation disorder. The heterozygote population. Acta Haemat 1974; 51: 40-50
• 8 Fair DS, Revak DJ, Hubbard JG, Girolami A. Isolation and characterization of the factor X Friuli variant. Blood 1989; 73: 2108-2116
• 9 James HL, Girolami A, Fair DS. Molecular defect in coagulation factor X Friuli results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-323
• 10 Beaucage SI, Caruthers MH. Deoxynucleoside phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahed Lett 1981; 22: 1859-1862
• 11 Kim DJ, James HL. Expression of human factor X with normal biological activity in human embryonic kidney cells. Biotech Lett 1994; 16: 549-554
• 12 Nelson RM, Long GL. A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. Anal Biochem 1989; 180: 147-151
• 13 Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1991
• 14 Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7: 2745-2752
• 15 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
• 16 Chattopadyay A, Fair DS. Molecular recognition in the activation of human blood coagulation factor X. J Biol Chem 1989; 264: 11035-11043
• 17 Kim DJ, Thompson AR, Nash DR, James HL. Factors XWenatchee I and II: compound heterozygosity involving two variant proteins. Biochim Biophys Acta 1995; 1271: 327-334
• 18 Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 1987; 262: 10035-10038
• 19 Przysiecki CT, Staggers JE, Ramit HG, Musson DG, Stem AM, Bennett CD, Friedman PA. Occurrence of p-hydroxylated asparagine residues in non-vitamin K-dependent proteins containing epidermal growth factor-like domains. Proc Natl Acad Sci USA 1987; 84: 7856-7860
• 20 Padmanabahn K, Padmanabahn KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human Des(l-45) factor Xa at 2.2 A resolution. J Mol Biol 1993; 232: 947-966
• 21 Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor) and protein S. Biochemistry 1977; 16: 698-706
• 22 James HL. Factor X. In: Haemostasis and Thrombosis, Vol 1. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Churchill Livingstone, Edinburgh 1994: 439-464
• 23 Toomey JR, Smith KJ, Stafford DW. Localization of the human tissue factor recognition determinant of human factor Vila. J Biol Chem 1991; 266: 19198-19202
• 24 Hamaguchi N, Charifson PS, Pedersen LG, Brayer GD, Smith KJ, Stafford DW. Expression and characterization of human factor IX. Factor IX and factor IXval_397 J Biol Chem 1991; 266: 15213-15220
• 25 Zhang L, Castellino FJ. A y-carboxyglutamic (7) variant (76D,77D) of human activated protein C displays greatly reduced activity as an anticoagulant. Biochemistry 1990; 29: 10828-10834
• 26 Walls JD, Berg DT, Yan SB, Grinnell BW. Amplification of multicistronic plasmids in the human 293 cell line and secretion of correctly processed recombinant protein C. Gene 1989; 81: 139-149
• 27 Morita T, Jackson CM. Localization of the structural difference between bovine blood coagulation factors X! and X2 to tyrosine 18 in the activation peptide. J Biol Chem 1986; 261: 4008-4014
• 28 Kraut J. Chymotrypsinogen: X-ray structure. In: The Enzymes, vol III. Boyer PD, ed. Academic Press, San Diego, CA 1983: 165-183
• 29 Alber T, Bell JA, Dao-Pin S, Nicholson H, Wozniak JA, Cook S, Matthews BW. Replacements of Pro86 in phage T4 lysozyme extend an a-helix but do not alter protein stability. Science 1988; 239: 631-635
• 30 Chattopadhyay A, James HL, Fair DS. Molecular recognition sites on factor X which participate in the prothrombinase complex. J Biol Chem 1992; 267: 12323-12329
• 31 Femlund P, Stenflo J. (3-hydroxyaspartic acid in vitamin K-dependent proteins. J Biol Chem 1983; 258: 12509-12512
• 32 Fung MR. Molecular genetics of blood coagulation factor X. PhD dissertation. University of British Columbia, Vancouver, Canada 1988